Biontech Se Stock Total Debt
| BNTX Stock | USD 86.81 0.64 0.74% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
Total Debt To Capitalization is likely to drop to 0.01 in 2024. BioNTech | Total Debt |
BioNTech SE Company Total Debt Analysis
BioNTech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current BioNTech Total Debt | 219.1 M |
Most of BioNTech's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
BioNTech Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for BioNTech is extremely important. It helps to project a fair market value of BioNTech Stock properly, considering its historical fundamentals such as Total Debt. Since BioNTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioNTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioNTech's interrelated accounts and indicators.
Click cells to compare fundamentals
BioNTech Total Debt Historical Pattern
Today, most investors in BioNTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BioNTech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of BioNTech total debt as a starting point in their analysis.
BioNTech Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
BioNTech Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, BioNTech SE has a Total Debt of 219.1 M. This is 92.04% lower than that of the Biotechnology sector and 32.54% lower than that of the Health Care industry. The total debt for all United States stocks is 95.88% higher than that of the company.
BioNTech Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in total debt category among related companies.
BioNTech Current Valuation Drivers
We derive many important indicators used in calculating different scores of BioNTech from analyzing BioNTech's financial statements. These drivers represent accounts that assess BioNTech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of BioNTech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 6.4B | 15.7B | 34.3B | 23.0B | 24.1B | |
| Enterprise Value | 2.5B | 5.9B | 14.7B | 20.6B | 11.5B | 7.7B |
BioNTech Institutional Holders
Institutional Holdings refers to the ownership stake in BioNTech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioNTech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioNTech's value.| Shares | Deutsche Bank Ag | 2023-09-30 | 546.5 K | Voloridge Investment Management, Llc | 2023-09-30 | 530.5 K | Millennium Management Llc | 2023-09-30 | 498.4 K | Clearbridge Advisors, Llc | 2023-09-30 | 484.1 K | Dekabank Deutsche Girozentrale | 2023-12-31 | 425.1 K | First Trust Advisors L.p. | 2023-12-31 | 416.9 K | Gilder Gagnon Howe & Co Llc | 2023-12-31 | 359.7 K | Bamco Inc | 2023-12-31 | 242.3 K | Fmr Inc | 2023-09-30 | 237.8 K | Baillie Gifford & Co Limited. | 2023-12-31 | 8.7 M | Primecap Management Company | 2023-12-31 | 4.8 M |
BioNTech Fundamentals
| Return On Equity | 0.0462 | ||||
| Return On Asset | 0.0262 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 4.21 B | ||||
| Shares Outstanding | 240.99 M | ||||
| Shares Owned By Insiders | 62.84 % | ||||
| Shares Owned By Institutions | 18.32 % | ||||
| Number Of Shares Shorted | 3.08 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 5.46 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 1.16 B | ||||
| Net Income | 1.19 B | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 219.1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 85.17 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Short Ratio | 4.33 X | ||||
| Earnings Per Share | 4.07 X | ||||
| Price To Earnings To Growth | 0.04 X | ||||
| Target Price | 118.25 | ||||
| Number Of Employees | 6.13 K | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 20.82 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with BioNTech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioNTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will appreciate offsetting losses from the drop in the long position's value.Moving together with BioNTech Stock
| 0.72 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.77 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
Moving against BioNTech Stock
| 0.56 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.51 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.48 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioNTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioNTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioNTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioNTech SE to buy it.
The correlation of BioNTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioNTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioNTech SE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioNTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BioNTech Piotroski F Score and BioNTech Altman Z Score analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 4.07 | Revenue Per Share 15.873 | Quarterly Revenue Growth (0.65) | Return On Assets 0.0262 |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.